Free Trial

Tango Therapeutics (TNGX) News Today

Tango Therapeutics logo
$1.27 -0.10 (-7.30%)
Closing price 04/3/2025 04:00 PM Eastern
Extended Trading
$1.26 -0.01 (-0.39%)
As of 04/3/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Tango Therapeutics, Inc. stock logo
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Expands By 29.4%
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 9,110,000 shares, an increase of 29.4% from the February 28th total of 7,040,000 shares. Approximately 15.4% of the shares of the company are sold short. Based on an average daily volume of 873,500 shares, the days-to-cover ratio is presently 10.4 days.
Barclays Sticks to Its Buy Rating for Tango Therapeutics (TNGX)
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Sees Large Growth in Short Interest
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 7,040,000 shares, a growth of 18.5% from the February 13th total of 5,940,000 shares. Approximately 11.9% of the shares of the stock are sold short. Based on an average daily volume of 967,300 shares, the short-interest ratio is currently 7.3 days.
Tango Therapeutics, Inc. stock logo
Cantor Fitzgerald Has Weak Estimate for TNGX FY2025 Earnings
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities researchers at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Monday, March 10th. Cantor Fitzgerald analyst E. Schmid
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday
Tango Therapeutics (NASDAQ:TNGX) will be releasing earnings before the market opens on Monday, March 17, Financial Modeling Prep reports.
Tango Therapeutics (TNGX) Receives a Buy from Barclays
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). Tango Therapeutics had a negative return on equity of 49.64% and a negative net margin of 284.42%.
Tango Therapeutics sees cash runway into 3Q26
Tango Therapeutics reports Q4 EPS (35c), consensus (34c)
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Recommendation of "Buy" from Brokerages
Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been given an average recommendation of "Buy" by the seven analysts that are currently covering the stock, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation. The averag
Tango Therapeutics, Inc. stock logo
Short Interest in Tango Therapeutics, Inc. (NASDAQ:TNGX) Decreases By 22.5%
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) saw a large decrease in short interest in January. As of January 31st, there was short interest totalling 5,440,000 shares, a decrease of 22.5% from the January 15th total of 7,020,000 shares. Based on an average daily trading volume, of 1,720,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 11.0% of the shares of the company are sold short.
Tango Therapeutics, Inc. stock logo
What is Leerink Partnrs' Forecast for TNGX Q3 Earnings?
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at Leerink Partnrs issued their Q3 2025 earnings per share (EPS) estimates for shares of Tango Therapeutics in a report released on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post ear
Tango Therapeutics, Inc. stock logo
What is Leerink Partnrs' Forecast for TNGX Q1 Earnings?
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for shares of Tango Therapeutics in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens anticipates that the company will post
Tango Therapeutics, Inc. stock logo
Daniella Beckman Sells 4,284 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) Stock
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) CFO Daniella Beckman sold 4,284 shares of the firm's stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $12,809.16. Following the completion of the transaction, the chief financial officer now owns 154,232 shares in the company, valued at $461,153.68. This represents a 2.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Sells $22,221.68 in Stock
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 7,432 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $2.99, for a total transaction of $22,221.68. Following the completion of the transaction, the insider now owns 165,061 shares of the company's stock, valued at $493,532.39. This trade represents a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) CEO Barbara Weber Sells 9,778 Shares
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) CEO Barbara Weber sold 9,778 shares of the stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $2.99, for a total value of $29,236.22. Following the completion of the sale, the chief executive officer now directly owns 1,631,264 shares of the company's stock, valued at approximately $4,877,479.36. This trade represents a 0.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Consensus Rating of "Buy" from Brokerages
Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have been given an average rating of "Buy" by the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Eight equities research analysts have rated the stock with a buy rating. The average twelve-mon
Tango Therapeutics: Chance For A Short Squeeze
Tango Therapeutics, Inc. stock logo
Analysts Set Expectations for TNGX FY2025 Earnings
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the
Tango Therapeutics, Inc. stock logo
State Street Corp Purchases 489,949 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX)
State Street Corp raised its stake in shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 26.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 2,318,208 shares of the company's stock after purchasing an additional 489,949 shares during the p
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Given Average Recommendation of "Buy" by Brokerages
Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price obj
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Update
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) was the target of a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 7,110,000 shares, a decrease of 21.7% from the October 31st total of 9,080,000 shares. Based on an average daily trading volume, of 1,840,000 shares, the days-to-cover ratio is presently 3.9 days. Approximately 14.4% of the company's stock are short sold.
Tango Therapeutics, Inc. stock logo
Trv Gp Iv LLC Has $129.82 Million Position in Tango Therapeutics, Inc. (NASDAQ:TNGX)
Trv Gp Iv LLC lessened its holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 12.2% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 16,859,075 shares of the company's stock after selling 2,342,400 shares duri
Tango Therapeutics, Inc. stock logo
Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives Average Rating of "Buy" from Analysts
Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) have earned an average rating of "Buy" from the eight research firms that are covering the company, Marketbeat.com reports. Eight research analysts have rated the stock with a buy rating. The average 12-month price target among bro
Tango Therapeutics, Inc. stock logo
B. Riley Boosts Earnings Estimates for Tango Therapeutics
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Analysts at B. Riley upped their FY2024 earnings per share estimates for shares of Tango Therapeutics in a research report issued on Monday, November 11th. B. Riley analyst Y. Zhi now forecasts that the company will earn ($1.21) per share for
Tango Therapeutics price target lowered to $8 from $16 at B. Riley
Tango Therapeutics, Inc. stock logo
B. Riley Cuts Tango Therapeutics (NASDAQ:TNGX) Price Target to $8.00
B. Riley dropped their target price on shares of Tango Therapeutics from $16.00 to $8.00 and set a "buy" rating for the company in a research report on Monday.
Tango Therapeutics, Inc. stock logo
FY2024 Earnings Forecast for TNGX Issued By Leerink Partnrs
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Equities research analysts at Leerink Partnrs lifted their FY2024 EPS estimates for Tango Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. Leerink Partnrs analyst A. Berens now expects that the com
Tango Therapeutics, Inc. stock logo
HC Wainwright Reaffirms Buy Rating for Tango Therapeutics (NASDAQ:TNGX)
HC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of Tango Therapeutics in a research note on Friday.
Tango Therapeutics, Inc. stock logo
Wedbush Forecasts Reduced Earnings for Tango Therapeutics
Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) - Investment analysts at Wedbush lowered their FY2024 EPS estimates for Tango Therapeutics in a research note issued on Wednesday, November 6th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($1.16) per share for the year
Tango Therapeutics price target lowered to $8 from $18 at Guggenheim
Tango Therapeutics Advances Cancer Treatment Pipeline
Tango Therapeutics, Inc. stock logo
Tango Therapeutics (NASDAQ:TNGX) Price Target Lowered to $8.00 at Guggenheim
Guggenheim cut their price objective on Tango Therapeutics from $18.00 to $8.00 and set a "buy" rating on the stock in a report on Thursday.
Tango Therapeutics announces update on PRMT5 program
Barclays Keeps Their Buy Rating on Tango Therapeutics (TNGX)
Remove Ads
Get Tango Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.

TNGX Media Mentions By Week

TNGX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

TNGX
News Sentiment

1.95

0.61

Average
Medical
News Sentiment

TNGX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

TNGX Articles
This Week

1

2

TNGX Articles
Average Week

Remove Ads
Get Tango Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TNGX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:TNGX) was last updated on 4/4/2025 by MarketBeat.com Staff
From Our Partners